[
    "ate (5.2 g) as a light yellow oil. </p>LCMS: C12H18O4S requires: 258, found: m/z = 259 [M+H]<sup>+</sup>. </p> [0290] Step 2: 3-hydroxypropyl 4-methylbenzenesulfonate. \n<img id=\"imgf000079_0002\" path=\"imgf000079_0002.tif\" file=\"https://surechembl.org/api/assets/attachment/766370260/WO/20200820/A1/002020/16/75/18/imgf000079_0002.tif\"/>\n </p> [0291] The procedure of Step 1 was followed to afford 3-hydroxypropyl </p>4-methylbenzenesulfonate as a colorless oil. The 3-hydroxypropyl 4-methylbenzenesulfonate is additionally available commercially. </p> [0292] Step 3: 7-hydroxyheptyl 4-methylbenzenesulfonate. \n<img id=\"imgf000079_0003\" path=\"imgf000079_0003.tif\" file=\"https://surechembl.org/api/assets/attachment/766370298/WO/20200820/A1/002020/16/75/18/imgf000079_0003.tif\"/>\n </p> [0293] The procedure of Step 1 was followed to afford 7-hydroxyheptyl </p>4-methylbenzenesulfonate (4.2 g) as a colorless oil. LCMS: C<sub>14</sub>H<sub>22</sub>O<sub>4</sub>S requires: 286, found: m/z = 287 [M+H]<sup>+</sup>. </p> [0294] Example 10: Synthesis of 2-(2,6-dioxopiperidin-3-yQ-5-(3- hydroxypropoxyMsoindoline-l,3-dione. \n<img id=\"imgf000079_0004\" path=\"imgf000079_0004.tif\" file=\"https://surechembl.org/api/assets/attachment/766370356/WO/20200820/A1/002020/16/75/18/imgf000079_0004.tif\"/>\n \n\n [0295] A mixture of 2-(2,6-dioxopiperidin-3-yl)-5-hydroxy-2,3-dihydro-lH-isoindole-l,3- dione (3.0 g, 10.9 mmol), 3-[(4-methylbenzenesulfonyl)oxy]propan-l-ol (5.0 g, 21.9 mmol), z-P^NEt (4.2 g, 32.8 mmol) and KI (182 mg, 1.09 mmol) in DMF (40 mL) was stirred at 80 \u00b0C for 16 h. The resulting mixture was cooled to rt and diluted with water. The aqueous phase was extracted with CH2CI2 and the combined organic layers were washed with brine, dried (Na2S04), filtered, and concentrated. The residue was purified (RP-SiCh, 5 50% ACN/H2O) to afford 2-(2,6-dioxopiperidin-3-yl)-5-(3-hydroxypropoxy)isoindoline-l,3-dione (1.8 g) as a white solid. </p> [0296] Example 11: Synthesis of 2- dioxopiperidin-3-vP-5-((5- \n<img id=\"imgf000080_0001\" path=\"imgf000080_0001.tif\" file=\"https://surechembl.org/api/assets/attachment/766370329/WO/20200820/A1/002020/16/75/18/imgf000080_0001.tif\"/>\n </p>hvdroxypentvPoxyMsoindoline-l.,3-dione. \n<img id=\"imgf000080_0002\" path=\"imgf000080_0002.tif\" file=\"https://surechembl.org/api/assets/attachment/766370322/WO/20200820/A1/002020/16/75/18/imgf000080_0002.tif\"/>\n </p> [0297] The procedure from Example 10 was followed to afford 2-(2,6-dioxopiperidin-3-yl)- 5-((5-hydroxypentyl)oxy)isoindoline-l,3-dione (1.46 g) as a white solid. LCMS: C18H20N2O6 requires: 360, found: m/z = 361 [M+H]<sup>+</sup>. \u00be NMR (300 MHz, DMSO-r/e) d 11.11 (s, 1H), 7.81 (d, 8.4 Hz, 1H), 7.40 (d, J= 2.4 Hz, 1H), 7.33 (dd, J= 8.4, 2.4 Hz, 1H), 5.15 - 5.09</p>(m, 1H), 4.38 (t, J = 5.1 Hz, 1H), 4.15 (t, J= 6.6 Hz, 2H), 3.39 (q, J= 5.7 Hz, 2H), 2.98 - 2.76 (m, 1H), 2.63 - 2.48 (m, 2H), 2.13 - 1.93 (m, 1H), 1.80 - 1.66 (m, 2H), 1.51 - 1.40 (m, 4H). </p> [0298] Example 12: Synthesis of 2- dioxopiperidin-3"
]